We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
Awakn Life Sciences Corp. (AWKN.NE)
| Previous Close | 0.2200 |
| Open | 0.2200 |
| Bid | 0.2050 x N/A |
| Ask | 0.2500 x N/A |
| Day's Range | 0.2000 - 0.2200 |
| 52 Week Range | 0.0550 - 0.7700 |
| Volume | |
| Avg. Volume | 68,458 |
| Market Cap | 8.123M |
| Beta (5Y Monthly) | 3.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2900 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NewsfileAwakn Life Sciences Receives Regulatory and Ethical Approval for Phase III Clinical Trial of AWKN-P001
AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use Disorder Toronto, Ontario--(Newsfile Corp. - November 15, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today that it has received clinical trial authorization from the Medicines
NewsfileAwakn Life Sciences Announces Receipt of Notice of Non-Compliance with Cboe Exchange Continued Listing Requirements
Toronto, Ontario--(Newsfile Corp. - November 10, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today that it has received a notice (the "Notice") from Cboe Canada ("Cboe") indicating that Awakn is not in compliance with Section 3.01(3) of Cboe's Listing Manual. Awakn has 90 days to address the non-compliance.The ...
NewsfileAwakn Life Sciences Engages Orphan Insight Ltd. to Advance Market Access, Pricing, and Reimbursement Strategies for AWKN-P001 Targeting Severe Alcohol Use Disorder
Toronto, Ontario--(Newsfile Corp. - October 31, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces it has engaged Orphan Insight Ltd ("Orphan Insight") to develop and advance market access, pricing, and reimbursement for Awakn's lead program AWKN-P001. AWKN-P001 targets Severe Alcohol Use Disorder (SAUD), the most chroni
NewsfileAwakn Life Sciences Completes MDMA Zydis(R) ODT Feasibility Study
Study Confirms MDMA Is Stable on Zydis(R) ODT and Suitable for Pre-Gastric Absorption Toronto, Ontario--(Newsfile Corp. - October 4, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), today announces it has completed a feasibility study for its proprietary formulation of MDMA using Catalent's Zydis® orally disintegrating tablet (O
- Market Exclusive
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Leafly challenged and triumphed against New York’s marijuana advertisement restrictions. Columbia Care rebranded as The Cannabist Co. and secured $25 million in private placement. Canopy Growth raised $25 million in a private placement offering. Key Takeaways; Psychedelic Sector Awakn’s CRO, Prof. David Nutt, delivered keynote at The Clinic of Change event. […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared first on Market Exclusive.
NewsfileAwakn Life Sciences Provides Corporate Update
Announces Closing of Third Tranche of Private Placement Toronto, Ontario--(Newsfile Corp. - September 14, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), shares a corporate update on recent progress. Awakn also announces the closing of the third tranche of its previously announced private placement.Key recent corporate activity
NewsfileAwakn Life Sciences Submits Clinical Trial Application for Phase III Trial of AWKN-P001
AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use Disorder Toronto, Ontario--(Newsfile Corp. - September 6, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today it has submitted the Clinical Trial Application (CTA) for a phase III tria
NewsfileAwakn Life Sciences Completes Sale of Awakn Clinics In Norway
Sale Completes Awakn's Exit From Healthcare Services To Focus Solely on Biotechnology Research and Development Toronto, Ontario--(Newsfile Corp. - August 1, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today the sale of its clinics businesses in Norway, comprising of Awakn Clinics Oslo and Awakn Cli
NewsfileAwakn Life Sciences Completes Sale of Awakn Clinics London
Licenses Awakn Kare and Certain Healthcare Intellectual Property Assets to New Owners Toronto, Ontario--(Newsfile Corp. - July 5, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today the sale of Awakn London Limited., Awakn's subsidiary that owns and operates its healthcare clinic in London, United Ki
NewsfileAwakn Life Sciences Announces Results of Annual General and Special Meeting
Toronto, Ontario--(Newsfile Corp. - June 27, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (the "Company"), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce the results of its annual general and special meeting of shareholders (the "Meeting") held earlier today.All matters presented for approval at the Meeting were duly authorized and approved, as follows:fixing
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| AWKNF Awakn Life Sciences Corp. | |||
| FH.NE Filament Health Corp. | |||
| CYBN.NE Cybin Inc. | |||
| PHRM.CN PharmaTher Holdings Ltd. | |||
| PSYC.CN Psyched Wellness Ltd. |
Similar to AWKN.NE
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| MESC.CN Lophos Holdings Inc. | |||
| MDMA.CN Pharmala Biotech Holdings Inc. | |||
| CYBN.NE Cybin Inc. | |||
| ASEP.CN ASEP Medical Holdings Inc. | |||
| TRYP.CN Tryp Therapeutics Inc. |
Company Profile
301-217 Queen Street West
Toronto, ON M5V 0R2
Canada
https://awaknlifesciences.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 44
Awakn Life Sciences Corp., a biotechnology company, engages in the researching, developing, operations, and delivering of psychedelic therapeutics to treat addiction and other mental health conditions in the United Kingdom and Europe. The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD. Awakn Life Sciences Corp. is headquartered in Toronto, Canada.
